Decisions That Made A Difference: Wockhardt Chief On A Life In Business

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

Dr Habil Khorakiwala, Wockhardt’s chair and group CEO, recounts his life and business journey, including an acquisition that went wrong, in an interview with Scrip as part of our ongoing executive profile series. Khorakiwala also outlines where he sees Wockhardt in the coming years, with the firm’s R&D thrust in the antibiotics space expected to play a pivotal role.

Habil Khorakiwala
WOCKHARDT CHAIR AND GROUP CEO DR HABIL KHORAKIWALA

Wockhardt’s founder chair and group CEO, Dr Habil Khorakiwala, believes learning from mistakes is as important as cherishing success. He has been candid enough to discuss with Scrip some of the troughs, as well as the peaks, along the corporate journey that has seen Wockhardt Ltd. emerge as a prominent Indian firm with sales of INR40.15bn ($630m) for the year ended March 2017.

In the latest instalment of our ongoing executive profile series, Khorakiwala recalls the early challenges around getting Worli Chemical Works...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Leadership

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Scrip-Leadership (Free-2): Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Nabil

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains